Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2025; 13(31): 110123
Published online Nov 6, 2025. doi: 10.12998/wjcc.v13.i31.110123
Published online Nov 6, 2025. doi: 10.12998/wjcc.v13.i31.110123
Role of anti-inflammatory agent colchicine in atherosclerotic cardiovascular disease
Kevan English, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States
Christine Uwibambe, Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, United States
Author contributions: English K wrote the original draft, contributed to conceptualization, writing, reviewing, and editing; Uwibambe C reviewed and edited the article. All authors read and approved the final version of the manuscript.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kevan English, MD, Department of Internal Medicine, University of Nebraska Medical Center, S 42nd & Emile St, Omaha, NE 68198, United States.
Received: May 30, 2025
Revised: June 15, 2025
Accepted: September 1, 2025
Published online: November 6, 2025
Processing time: 154 Days and 3.6 Hours
Revised: June 15, 2025
Accepted: September 1, 2025
Published online: November 6, 2025
Processing time: 154 Days and 3.6 Hours
Core Tip
Core Tip: Inflammation is now recognized as an essential component of atherosclerosis, and the anti-inflammatory agent colchicine, through a variety of actions, suppresses this response. Results from a meta-analysis of several randomized controlled trials that evaluated colchicine’s efficacy on cardiovascular outcomes led to its recent approval by the United States Food and Drug Administration for the management and prevention of atherosclerotic cardiovascular disease. It has been shown to reduce the risk of recurrent major adverse cardiovascular events, and clinical data now supports its use for secondary prevention in patients with established coronary artery disease, presumably due to its anti-inflammatory properties.